We recently reported that oncogenic RAS (K-RASG13D and H-RASG12V), via its PI3K/AKT/mTOR/CK1α effector pathway, downregulates FOXO3A protein abundance in human cancer cells. This evidence concerns the gene FOXO3 and cancer.